Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2006

View Archived Issues

Pro-antioxidant effects of resveratrol in cardiovascular tissue

Targeting Hsp90 to selectively degrade mutated B-Raf for melanoma

Procyon receives NRC-IRAP contribution for development of PPL-100

FDA approves CIP-Fenofibrate

Genelabs discusses Prestara development options with FDA

Evotec and Boehringer Ingelheim expand drug discovery collaboration

4SC and Sanwa Kagaku Kenkyusho achieve drug discovery collaboration milestone

Avigen signs North American deal for neuroactive compound

Positive findings in phase III study of Pennsaid

Clearance for phase I study of PRX-302 in prostate cancer

Series D financing at Symphogen

NMDA NR2B receptors contribute to behavioral sensitization evoked by inflammation

Ropinirole efficacy in restless legs syndrome affirmed in large trial

Letrozole superior to tamoxifen in postmenopausal women with breast cancer

Oral contraceptives may lead to sex hormone-binding globulin elevation

Inhaled ciclosporin added to immunosuppression beneficial in lung transplant patients

Medicure reports corporate highlights from quarter

Recent patents report new treatments for thrombotic disorders

Fast track designation for peramivir in the treatment of influenza infections

Novel CCR4 receptor modulators emerge from Astellas R&D

European roll-out of Serdolect begins in Estonia

Agents with potential for HIV infection treatment revealed in recent patents

First pure heart rate-lowering agent launched in Ireland

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...